[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
[2] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
[3] |
钱波. 我国乳腺癌筛查及药物预防的现状及进展[J]. 中国妇幼保健,2019, 34(23): 5558-5561.
|
[4] |
Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC [J]. Cancers (Basel), 2020, 12(4):916.
|
[5] |
孙晓萌,高社干. 三阴性乳腺癌的临床治疗现状及新进展[J]. 实用癌症杂志,2020, 35(6): 1037-1039.
|
[6] |
O’reilly EA, Gubbins L, Sharma S, et al. The fate of chemoresistance in triple negative breast cancer (TNBC)[J]. BBA Clin, 2015, 3: 257-275.
|
[7] |
Ikonen E. Cellular cholesterol trafficking and compartmentalization[J]. Nat Rev Mol Cell Biol, 2008, 9(2): 125-138.
|
[8] |
Wang Y, Rogers PM, Su C, et al. Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha[J]. J Biol Chem, 2008, 283(39): 26 332-26 339.
|
[9] |
Kolanjiappan K, Ramachandran CR, Manoharan S. Biochemical changes in tumor tissues of oral cancer patients[J]. Clin Biochem, 2003, 36(1): 61-65.
|
[10] |
He M, Zhang W, Dong Y, et al. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 15.
|
[11] |
Kim J, Thompson B, Han S, et al. Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(12): 158 525.
|
[12] |
Munir MT, Ponce C, Powell CA, et al. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer[J]. J Steroid Biochem Mol Biol, 2018, 183: 1-9.
|
[13] |
Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells[J]. Mol Cancer Ther, 2001, 1(2): 141-149.
|
[14] |
Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway[J]. Biochem Pharmacol, 2008, 75(4): 907-913.
|
[15] |
Chen X, Liu Y, Wu J, et al. Mechanistic study of inhibitory effects of atorvastatin and docetaxel in combination on prostate cancer[J]. Cancer Genomics Proteomics, 2016, 13(2): 151-160.
|
[16] |
Werner M, Sacher J, Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells[J]. Br J Pharmacol, 2004, 143(6): 715-724.
|
[17] |
International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new casesand 10.0 million cancer deaths in 2020[EB/OL]. [2020-12-15].
URL
|
[18] |
Kobayashi Y, Kashima H, Rahmanto YS, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer[J]. Oncotarget, 2017, 8(42): 72147-72156.
|
[19] |
王玲,周巧直,王晓燕. 阿托伐他汀调控MMP-9、Cleaved Caspase-3、Bcl-2和Bax蛋白表达对胃癌细胞增殖、周期和凋亡的影响[J]. 胃肠病学和肝病学杂志,2018, 27(11): 1206-1210.
|
[20] |
Langballe R, Cronin-fenton D, Dehlendorff C, et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study[J]. Br J Cancer, 2018, 119(10): 1297-1305.
|
[21] |
Borgquist S, Broberg P, Tojjar J, et al. Statin use and breast cancer survival - a Swedish nationwide study[J]. BMC Cancer, 2019, 19(1): 54.
|
[22] |
Beckwitt CH, Brufsky A, Oltvai ZN, et al. Statin drugs to reduce breast cancer recurrence and mortality[J]. Breast Cancer Res, 2018, 20(1): 144.
|
[23] |
Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway[J]. Oncotarget, 2016, 7(3): 2532-2544.
|
[24] |
Feldt M, Bjarnadottir O, Kimbung S, et al. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial[J]. J Transl Med, 2015, 13: 133.
|
[25] |
Sato R. Sterol metabolism and SREBP activation[J]. Arch Biochem Biophys, 2010, 501(2): 177-181.
|
[26] |
Bovenga F, Sabbà C, Moschetta A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer[J]. Cell Metab, 2015, 21(4): 517-526.
|
[27] |
Silvente-poirot S, Poirot M. Cancer. Cholesterol and cancer, in the balance[J]. Science, 2014, 343(6178): 1445-1446.
|